Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomann R, Zechmann S, Alexander-David N, Jornayvaz FR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	insulin glargine 300 u/ml type 2 diabetes real-world switzerland Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5a0f4f0a7b346c38eb61152ac5c83cc
record_format	dspace
spelling	oai:doaj.org-article:a5a0f4f0a7b346c38eb61152ac5c83cc2021-12-02T10:59:47ZReal-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland1178-7007https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc2020-07-01T00:00:00Zhttps://www.dovepress.com/real-world-effectiveness-of-insulin-glargine-300-initiation-in-switzer-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvaz@hcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, SwitzerlandThomann RZechmann SAlexander-David NJornayvaz FRDove Medical Pressarticleinsulin glargine 300 u/mltype 2 diabetesreal-worldswitzerlandSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 2359-2365 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	insulin glargine 300 u/ml type 2 diabetes real-world switzerland Specialties of internal medicine RC581-951
spellingShingle	insulin glargine 300 u/ml type 2 diabetes real-world switzerland Specialties of internal medicine RC581-951 Thomann R Zechmann S Alexander-David N Jornayvaz FR Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
description	Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvaz@hcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland
format	article
author	Thomann R Zechmann S Alexander-David N Jornayvaz FR
author_facet	Thomann R Zechmann S Alexander-David N Jornayvaz FR
author_sort	Thomann R
title	Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
title_short	Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
title_full	Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
title_fullStr	Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
title_full_unstemmed	Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
title_sort	real-world effectiveness of insulin glargine 300 initiation in switzerland
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc
work_keys_str_mv	AT thomannr realworldeffectivenessofinsulinglargine300initiationinswitzerland AT zechmanns realworldeffectivenessofinsulinglargine300initiationinswitzerland AT alexanderdavidn realworldeffectivenessofinsulinglargine300initiationinswitzerland AT jornayvazfr realworldeffectivenessofinsulinglargine300initiationinswitzerland
_version_	1718396370466897920

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

Ejemplares similares